Myriad Genetics (NASDAQ:MYGN), headquartered in Salt Lake City, Utah, is a global leader in molecular diagnostics committed to transforming health care through predictive medicine. Founded in 1991, the company has grown from its early focus on hereditary cancer testing to a broad portfolio of genetic assays that inform disease risk assessment, diagnosis and treatment decisions. Myriad’s mission is to provide clinicians and patients with accurate, actionable insights to guide personalized care.
Myriad’s core offerings include hereditary cancer risk tests such as BRACAnalysis CDx, which evaluates BRCA1 and BRCA2 gene mutations linked to breast and ovarian cancer, and myRisk, a multi-gene panel that assesses predisposition to a range of cancers. Beyond oncology, the company markets Prolaris, a prognostic test for prostate cancer, and EndoPredict, which predicts breast cancer recurrence risk. In the neurology and psychiatry space, Myriad’s GeneSight pharmacogenomic test helps clinicians tailor medication choices for patients with depression, anxiety and related disorders.
With operations spanning North America, Europe, Asia Pacific and Latin America, Myriad serves a diverse network of hospitals, academic centers and reference laboratories. The company engages in strategic collaborations with pharmaceutical firms and research institutions to develop companion diagnostics and support clinical trials. Under the leadership of President and CEO Mark T. Capone, Myriad continues to invest in research and technology, aiming to expand its test menu and bring new genomic solutions to markets worldwide.
